Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CUL4A | Q13619 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28052753 | 0.81 | ALDH1A1 (0.34) | CUL4AALDH1A1GAASMN1; SMN2TDP1 | |
| SCHEMBL20096385 | 0.67 | TDP1 (0.47) | ALDH1A1GAASMN1; SMN2TDP1KMT2A | |
| SCHEMBL6137178 | 0.60 | ELANE (0.43) | CUL4AALDH1A1GAATDP1KMT2A | |
| SCHEMBL10153183 | 0.60 | GAA (0.56) | GAASMN1; SMN2TDP1KMT2AMAPT | |
| SCHEMBL13118736 | 0.60 | TDP1 (0.57) | ALDH1A1GAASMN1; SMN2TDP1KMT2A | |
| SCHEMBL14248201 | 0.59 | GAA (0.55) | GAASMN1; SMN2TDP1KMT2AMAPT | |
| SCHEMBL10330877 | 0.57 | TDP1 (0.53) | ALDH1A1GAASMN1; SMN2TDP1KMT2A | |
| SCHEMBL2647640 | 0.56 | CACNA1F (0.44) | GAATDP1KMT2AMAPTMEN1 | |
| SCHEMBL7185278 | 0.55 | CUL4A (0.37) | CUL4AALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL2344407 | 0.54 | KCNH2 (0.43) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135859-B | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-113135859-A | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2021-07-20 | — | — | CN | claimed |
| CN-113135859-B | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-113135859-B | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-113135859-A | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-113135859-A | Green synthesis method of rosuvastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | HMGCR, CYP11B1, OSBP | CUL4A 148/4885ALDH1A1 1322/4885GAA 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.